Dennis Scolnik
Concepts (499)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of publications
|
Most Recent Publication
|
Publications by all authors
|
Concept score
|
Why?
|
---|
Fever | 15 | 2020 | 180 | 2.770 |
Why?
| Emergency Service, Hospital | 22 | 2020 | 464 | 2.730 |
Why?
| Hospitals, Pediatric | 27 | 2020 | 464 | 2.470 |
Why?
| Acetaminophen | 5 | 2008 | 40 | 1.560 |
Why?
| Students, Medical | 3 | 2016 | 52 | 1.380 |
Why?
| Pain | 5 | 2017 | 510 | 1.300 |
Why?
| Humans | 96 | 2020 | 36991 | 1.260 |
Why?
| Materia Medica | 2 | 2014 | 3 | 1.230 |
Why?
| Male | 64 | 2020 | 21496 | 1.100 |
Why?
| Education, Medical, Undergraduate | 2 | 2014 | 39 | 1.010 |
Why?
| Analgesics, Non-Narcotic | 3 | 2008 | 38 | 0.990 |
Why?
| Retrospective Studies | 33 | 2020 | 5211 | 0.940 |
Why?
| Child, Preschool | 46 | 2020 | 11262 | 0.930 |
Why?
| Infant | 40 | 2020 | 9298 | 0.920 |
Why?
| Female | 60 | 2020 | 22252 | 0.920 |
Why?
| Lidocaine | 2 | 2013 | 56 | 0.910 |
Why?
| Global Health | 2 | 2014 | 231 | 0.910 |
Why?
| Drug Overdose | 5 | 2019 | 21 | 0.880 |
Why?
| Curriculum | 3 | 2016 | 120 | 0.880 |
Why?
| Anesthetics, Local | 2 | 2013 | 99 | 0.860 |
Why?
| Pain Management | 3 | 2017 | 195 | 0.850 |
Why?
| Health Services Misuse | 1 | 2018 | 10 | 0.840 |
Why?
| Adolescent | 38 | 2020 | 12453 | 0.840 |
Why?
| Emergency Medicine | 4 | 2016 | 44 | 0.820 |
Why?
| Child | 51 | 2020 | 16704 | 0.810 |
Why?
| Lanolin | 1 | 2017 | 1 | 0.780 |
Why?
| Nipples | 1 | 2017 | 4 | 0.780 |
Why?
| Tooth Injuries | 1 | 2017 | 7 | 0.780 |
Why?
| Emollients | 1 | 2017 | 3 | 0.770 |
Why?
| Attitude of Health Personnel | 2 | 2016 | 212 | 0.750 |
Why?
| Physostigmine | 2 | 2016 | 2 | 0.730 |
Why?
| Ibuprofen | 2 | 2008 | 17 | 0.730 |
Why?
| Health Services Accessibility | 1 | 2018 | 174 | 0.720 |
Why?
| Cultural Diversity | 1 | 2016 | 16 | 0.720 |
Why?
| Bioethics | 1 | 2016 | 10 | 0.720 |
Why?
| Physician-Patient Relations | 2 | 2015 | 60 | 0.720 |
Why?
| Politics | 1 | 2016 | 16 | 0.720 |
Why?
| Seizures | 3 | 2019 | 312 | 0.710 |
Why?
| Belladonna Alkaloids | 1 | 2016 | 1 | 0.700 |
Why?
| Naphthoquinones | 1 | 2016 | 1 | 0.700 |
Why?
| Dermatitis, Allergic Contact | 1 | 2016 | 3 | 0.700 |
Why?
| Tertiary Care Centers | 4 | 2019 | 87 | 0.690 |
Why?
| Hospitals, Community | 1 | 2015 | 8 | 0.670 |
Why?
| Education, Medical | 1 | 2016 | 66 | 0.670 |
Why?
| Atropa belladonna | 1 | 2014 | 1 | 0.650 |
Why?
| Tertiary Healthcare | 10 | 2020 | 27 | 0.620 |
Why?
| Breast Feeding | 1 | 2017 | 231 | 0.620 |
Why?
| Vomiting | 3 | 2016 | 109 | 0.620 |
Why?
| Antivenins | 3 | 2019 | 3 | 0.610 |
Why?
| International Educational Exchange | 2 | 2014 | 5 | 0.610 |
Why?
| Diarrhea | 3 | 2018 | 180 | 0.610 |
Why?
| Vitamin K 1 | 1 | 2013 | 2 | 0.600 |
Why?
| Professional Competence | 1 | 2014 | 18 | 0.600 |
Why?
| Epinephrine | 1 | 2013 | 37 | 0.600 |
Why?
| Hematoma | 1 | 2013 | 17 | 0.600 |
Why?
| Tetracaine | 1 | 2013 | 23 | 0.600 |
Why?
| Primary Health Care | 2 | 2018 | 173 | 0.600 |
Why?
| Plant Preparations | 1 | 2013 | 4 | 0.590 |
Why?
| Pneumonia, Aspiration | 1 | 2013 | 7 | 0.590 |
Why?
| Anti-Bacterial Agents | 8 | 2019 | 575 | 0.590 |
Why?
| Lightning Injuries | 1 | 2013 | 1 | 0.590 |
Why?
| Burns, Electric | 1 | 2013 | 2 | 0.590 |
Why?
| Hospitals, Urban | 1 | 2013 | 7 | 0.590 |
Why?
| Canada | 7 | 2018 | 2142 | 0.580 |
Why?
| Disease Management | 1 | 2015 | 187 | 0.580 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2013 | 8 | 0.580 |
Why?
| Cholestasis | 1 | 2013 | 58 | 0.570 |
Why?
| Hemorrhage | 2 | 2019 | 175 | 0.570 |
Why?
| Albuterol | 1 | 2013 | 52 | 0.560 |
Why?
| Respiratory Distress Syndrome, Newborn | 1 | 2013 | 81 | 0.560 |
Why?
| Hallucinogens | 1 | 2012 | 3 | 0.560 |
Why?
| Datura stramonium | 1 | 2012 | 2 | 0.560 |
Why?
| Airway Obstruction | 1 | 2013 | 75 | 0.550 |
Why?
| Biomedical Research | 2 | 2016 | 200 | 0.540 |
Why?
| Pediatrics | 6 | 2016 | 983 | 0.540 |
Why?
| Practice Guidelines as Topic | 2 | 2015 | 482 | 0.530 |
Why?
| Air Ambulances | 1 | 2011 | 1 | 0.500 |
Why?
| Transportation of Patients | 1 | 2011 | 10 | 0.500 |
Why?
| Prosthesis Failure | 1 | 2011 | 49 | 0.500 |
Why?
| Infant, Newborn | 13 | 2019 | 5611 | 0.490 |
Why?
| Intubation, Gastrointestinal | 1 | 2011 | 49 | 0.490 |
Why?
| Pyloric Stenosis, Hypertrophic | 1 | 2010 | 14 | 0.480 |
Why?
| Penicillins | 2 | 2016 | 21 | 0.470 |
Why?
| Ileal Diseases | 2 | 2020 | 20 | 0.450 |
Why?
| Hemolytic-Uremic Syndrome | 1 | 2010 | 59 | 0.440 |
Why?
| Acute Kidney Injury | 1 | 2010 | 48 | 0.440 |
Why?
| Enteral Nutrition | 1 | 2011 | 174 | 0.430 |
Why?
| Methadone | 1 | 2009 | 6 | 0.430 |
Why?
| Baths | 1 | 2009 | 5 | 0.430 |
Why?
| Narcotics | 1 | 2009 | 14 | 0.430 |
Why?
| Intussusception | 2 | 2020 | 57 | 0.430 |
Why?
| Ultrasonography, Doppler | 1 | 2010 | 87 | 0.430 |
Why?
| Snake Bites | 2 | 2019 | 3 | 0.410 |
Why?
| Viper Venoms | 2 | 2019 | 4 | 0.410 |
Why?
| Pneumonia | 3 | 2014 | 108 | 0.390 |
Why?
| Treatment Outcome | 12 | 2019 | 4078 | 0.380 |
Why?
| Medication Errors | 5 | 2006 | 44 | 0.380 |
Why?
| Prospective Studies | 13 | 2018 | 2402 | 0.380 |
Why?
| Communication | 3 | 2016 | 110 | 0.380 |
Why?
| Endemic Diseases | 2 | 2004 | 13 | 0.370 |
Why?
| Administration, Oral | 5 | 2019 | 248 | 0.370 |
Why?
| Radiography | 6 | 2020 | 513 | 0.360 |
Why?
| Humidity | 1 | 2006 | 8 | 0.360 |
Why?
| Croup | 1 | 2006 | 10 | 0.350 |
Why?
| Hypoglycemia | 3 | 2012 | 63 | 0.350 |
Why?
| Anesthesia, Local | 1 | 2005 | 21 | 0.330 |
Why?
| Nebulizers and Vaporizers | 1 | 2006 | 83 | 0.330 |
Why?
| Leptospirosis | 1 | 2004 | 2 | 0.330 |
Why?
| Disease Reservoirs | 1 | 2004 | 2 | 0.330 |
Why?
| Meat | 1 | 2004 | 8 | 0.320 |
Why?
| Rodentia | 1 | 2004 | 5 | 0.320 |
Why?
| Bacterial Infections | 2 | 2017 | 136 | 0.320 |
Why?
| Program Evaluation | 2 | 2016 | 159 | 0.310 |
Why?
| Middle East | 2 | 2016 | 8 | 0.310 |
Why?
| Hypokalemia | 3 | 2013 | 5 | 0.300 |
Why?
| Genitalia, Male | 1 | 2003 | 9 | 0.300 |
Why?
| Genitalia, Female | 1 | 2003 | 13 | 0.300 |
Why?
| Yaws | 1 | 2003 | 1 | 0.290 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2003 | 213 | 0.290 |
Why?
| Incidence | 6 | 2017 | 847 | 0.290 |
Why?
| Naloxone | 2 | 2015 | 13 | 0.270 |
Why?
| Pain Measurement | 3 | 2018 | 384 | 0.270 |
Why?
| Severity of Illness Index | 6 | 2014 | 1309 | 0.270 |
Why?
| Drug Prescriptions | 3 | 2006 | 18 | 0.270 |
Why?
| Parenting | 1 | 2002 | 37 | 0.270 |
Why?
| Asthma | 4 | 2010 | 427 | 0.270 |
Why?
| Sulfonylurea Compounds | 2 | 2012 | 5 | 0.260 |
Why?
| Israel | 5 | 2020 | 32 | 0.260 |
Why?
| Foreign-Body Migration | 2 | 2012 | 33 | 0.250 |
Why?
| Leukocyte Count | 3 | 2017 | 57 | 0.250 |
Why?
| Anticonvulsants | 2 | 2019 | 199 | 0.250 |
Why?
| Caregivers | 1 | 2003 | 172 | 0.250 |
Why?
| Ventriculoperitoneal Shunt | 2 | 2012 | 47 | 0.250 |
Why?
| Ontario | 6 | 2013 | 1778 | 0.240 |
Why?
| Abdominal Pain | 2 | 2018 | 55 | 0.240 |
Why?
| Retropharyngeal Abscess | 1 | 2020 | 6 | 0.240 |
Why?
| Ultrasonography | 5 | 2020 | 623 | 0.230 |
Why?
| Drowning | 1 | 2020 | 18 | 0.230 |
Why?
| Publications | 1 | 2019 | 11 | 0.230 |
Why?
| Neck | 1 | 2020 | 44 | 0.230 |
Why?
| Community-Acquired Infections | 3 | 2014 | 37 | 0.220 |
Why?
| Disseminated Intravascular Coagulation | 1 | 2019 | 9 | 0.220 |
Why?
| Rivaroxaban | 1 | 2019 | 3 | 0.220 |
Why?
| Valproic Acid | 1 | 2019 | 12 | 0.220 |
Why?
| Hyperammonemia | 1 | 2019 | 18 | 0.220 |
Why?
| Factor Xa Inhibitors | 1 | 2019 | 9 | 0.220 |
Why?
| Encephalomyelitis, Acute Disseminated | 1 | 2019 | 16 | 0.220 |
Why?
| Insect Bites and Stings | 1 | 2019 | 1 | 0.220 |
Why?
| Hypoglycemic Agents | 2 | 2010 | 70 | 0.220 |
Why?
| Bites and Stings | 1 | 2018 | 3 | 0.210 |
Why?
| Guideline Adherence | 2 | 2010 | 88 | 0.210 |
Why?
| Venoms | 1 | 2018 | 7 | 0.210 |
Why?
| Carnitine | 1 | 2019 | 46 | 0.210 |
Why?
| Neurologic Examination | 1 | 2019 | 92 | 0.210 |
Why?
| Orbital Cellulitis | 1 | 2019 | 15 | 0.210 |
Why?
| Pneumococcal Vaccines | 2 | 2016 | 26 | 0.210 |
Why?
| Antidotes | 3 | 2015 | 6 | 0.210 |
Why?
| Young Adult | 3 | 2018 | 2527 | 0.210 |
Why?
| Cross-Sectional Studies | 2 | 2018 | 1214 | 0.210 |
Why?
| Triage | 1 | 2018 | 25 | 0.210 |
Why?
| Pilot Projects | 3 | 2017 | 499 | 0.210 |
Why?
| Flatulence | 1 | 2018 | 2 | 0.200 |
Why?
| Motivation | 1 | 2018 | 49 | 0.200 |
Why?
| Lactose Intolerance | 1 | 2018 | 7 | 0.200 |
Why?
| Lactose | 1 | 2018 | 11 | 0.200 |
Why?
| Isoniazid | 1 | 2018 | 8 | 0.200 |
Why?
| Phenytoin | 2 | 1997 | 14 | 0.200 |
Why?
| Pyridoxine | 1 | 2018 | 18 | 0.200 |
Why?
| Spider Bites | 1 | 2017 | 1 | 0.200 |
Why?
| Black Widow Spider | 1 | 2017 | 1 | 0.200 |
Why?
| Spider Venoms | 1 | 2017 | 2 | 0.200 |
Why?
| Age Factors | 5 | 2020 | 1477 | 0.200 |
Why?
| Carbamazepine | 2 | 1997 | 19 | 0.200 |
Why?
| Vitamin B Complex | 1 | 2018 | 15 | 0.200 |
Why?
| Antitubercular Agents | 1 | 2018 | 26 | 0.200 |
Why?
| Myositis | 1 | 2018 | 39 | 0.200 |
Why?
| Antipyretics | 1 | 2017 | 6 | 0.200 |
Why?
| Tachycardia | 1 | 2017 | 25 | 0.190 |
Why?
| Surveys and Questionnaires | 3 | 2018 | 1305 | 0.190 |
Why?
| Patient Outcome Assessment | 1 | 2017 | 38 | 0.190 |
Why?
| Escherichia coli | 2 | 2010 | 232 | 0.190 |
Why?
| Brain Diseases | 1 | 2019 | 145 | 0.190 |
Why?
| Administration, Topical | 1 | 2017 | 58 | 0.190 |
Why?
| Developing Countries | 2 | 2011 | 301 | 0.190 |
Why?
| Heart Arrest | 2 | 2020 | 96 | 0.190 |
Why?
| Intestine, Large | 2 | 2020 | 9 | 0.190 |
Why?
| Cohort Studies | 7 | 2018 | 2025 | 0.190 |
Why?
| Sex Distribution | 1 | 2017 | 144 | 0.190 |
Why?
| Guyana | 3 | 2010 | 4 | 0.180 |
Why?
| Neuroleptic Malignant Syndrome | 1 | 2016 | 3 | 0.180 |
Why?
| Mastoiditis | 1 | 2016 | 9 | 0.180 |
Why?
| Streptococcus pneumoniae | 1 | 2016 | 22 | 0.180 |
Why?
| Age Distribution | 1 | 2017 | 183 | 0.180 |
Why?
| Metoclopramide | 1 | 2016 | 7 | 0.180 |
Why?
| Heart Rate | 1 | 2017 | 181 | 0.180 |
Why?
| Salmonella paratyphi A | 1 | 2016 | 15 | 0.180 |
Why?
| Group Processes | 1 | 2016 | 9 | 0.180 |
Why?
| Evaluation Studies as Topic | 1 | 2016 | 90 | 0.180 |
Why?
| Neutropenia | 1 | 2017 | 141 | 0.180 |
Why?
| Lung | 2 | 2013 | 805 | 0.180 |
Why?
| Salmonella typhi | 1 | 2016 | 42 | 0.180 |
Why?
| Phenylenediamines | 1 | 2016 | 2 | 0.180 |
Why?
| Religion | 1 | 2016 | 4 | 0.180 |
Why?
| Focus Groups | 1 | 2016 | 97 | 0.180 |
Why?
| Immunoglobulin G | 1 | 2017 | 157 | 0.180 |
Why?
| Prenatal Exposure Delayed Effects | 2 | 1997 | 173 | 0.170 |
Why?
| Culture | 1 | 2016 | 19 | 0.170 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 579 | 0.170 |
Why?
| Antiemetics | 1 | 2016 | 69 | 0.170 |
Why?
| Typhoid Fever | 1 | 2016 | 66 | 0.170 |
Why?
| Octreotide | 2 | 2012 | 20 | 0.170 |
Why?
| Leukocytosis | 1 | 2015 | 10 | 0.170 |
Why?
| Diagnostic Errors | 1 | 2016 | 54 | 0.170 |
Why?
| Mothers | 1 | 2017 | 167 | 0.170 |
Why?
| Pseudotumor Cerebri | 1 | 2015 | 7 | 0.160 |
Why?
| Atropine | 1 | 2015 | 12 | 0.160 |
Why?
| Anticholinergic Syndrome | 1 | 2014 | 1 | 0.160 |
Why?
| Clonidine | 1 | 2015 | 11 | 0.160 |
Why?
| Follow-Up Studies | 3 | 2017 | 2650 | 0.160 |
Why?
| Colic | 1 | 2014 | 5 | 0.160 |
Why?
| Midazolam | 1 | 2014 | 12 | 0.160 |
Why?
| Benzodiazepines | 1 | 2014 | 17 | 0.160 |
Why?
| Fentanyl | 1 | 2014 | 21 | 0.160 |
Why?
| Appendicitis | 1 | 2016 | 77 | 0.160 |
Why?
| Methemoglobinemia | 1 | 2014 | 8 | 0.160 |
Why?
| Propofol | 1 | 2014 | 43 | 0.160 |
Why?
| Ascorbic Acid | 1 | 2014 | 20 | 0.160 |
Why?
| Practice Patterns, Physicians' | 2 | 2009 | 264 | 0.160 |
Why?
| Cefuroxime | 1 | 2014 | 5 | 0.150 |
Why?
| Penicillin G | 1 | 2014 | 9 | 0.150 |
Why?
| Antioxidants | 1 | 2014 | 43 | 0.150 |
Why?
| Colonoscopy | 1 | 2014 | 49 | 0.150 |
Why?
| Cultural Competency | 1 | 2014 | 9 | 0.150 |
Why?
| International Normalized Ratio | 1 | 2013 | 7 | 0.150 |
Why?
| Antifibrinolytic Agents | 1 | 2013 | 7 | 0.150 |
Why?
| Decision Making | 2 | 2019 | 205 | 0.150 |
Why?
| Electric Injuries | 1 | 2013 | 1 | 0.150 |
Why?
| Narcotic Antagonists | 2 | 2015 | 14 | 0.150 |
Why?
| Levodopa | 1 | 2013 | 6 | 0.150 |
Why?
| Blood Coagulation Disorders | 1 | 2013 | 24 | 0.150 |
Why?
| Wit and Humor as Topic | 1 | 2013 | 5 | 0.150 |
Why?
| Chlorides | 2 | 2010 | 120 | 0.150 |
Why?
| Basal Ganglia Diseases | 1 | 2013 | 15 | 0.150 |
Why?
| Drug Therapy, Combination | 2 | 2018 | 264 | 0.150 |
Why?
| Injections, Intravenous | 1 | 2013 | 104 | 0.150 |
Why?
| Debridement | 1 | 2013 | 13 | 0.150 |
Why?
| Bandages | 1 | 2013 | 19 | 0.150 |
Why?
| Arm Injuries | 1 | 2013 | 12 | 0.150 |
Why?
| Animals | 7 | 2020 | 7811 | 0.150 |
Why?
| Leg Injuries | 1 | 2013 | 7 | 0.140 |
Why?
| Peer Group | 1 | 2014 | 63 | 0.140 |
Why?
| Cooperative Behavior | 1 | 2014 | 92 | 0.140 |
Why?
| Program Development | 1 | 2014 | 97 | 0.140 |
Why?
| Interviews as Topic | 1 | 2014 | 175 | 0.140 |
Why?
| Anti-Asthmatic Agents | 2 | 2010 | 47 | 0.140 |
Why?
| Physical Examination | 1 | 2013 | 88 | 0.140 |
Why?
| Peritoneal Dialysis | 1 | 1993 | 28 | 0.140 |
Why?
| Time Factors | 4 | 2019 | 2225 | 0.140 |
Why?
| Serum Albumin | 1 | 1993 | 52 | 0.140 |
Why?
| Plant Poisoning | 1 | 2012 | 1 | 0.140 |
Why?
| Administration, Rectal | 2 | 2002 | 5 | 0.140 |
Why?
| Cholinesterase Inhibitors | 1 | 2012 | 6 | 0.140 |
Why?
| Adult | 6 | 2018 | 6268 | 0.140 |
Why?
| Potassium | 1 | 1993 | 85 | 0.140 |
Why?
| Glyburide | 2 | 2010 | 7 | 0.140 |
Why?
| Catheterization | 1 | 2013 | 138 | 0.140 |
Why?
| Hyponatremia | 1 | 2012 | 17 | 0.140 |
Why?
| Lung Abscess | 1 | 2012 | 1 | 0.140 |
Why?
| Mycobacterium fortuitum | 1 | 2012 | 2 | 0.140 |
Why?
| Hyperglycemia | 1 | 2013 | 65 | 0.140 |
Why?
| Benchmarking | 1 | 2012 | 30 | 0.130 |
Why?
| Prevalence | 3 | 2020 | 769 | 0.130 |
Why?
| Pleural Cavity | 1 | 2012 | 5 | 0.130 |
Why?
| Hydrothorax | 1 | 2012 | 5 | 0.130 |
Why?
| Dyspnea | 1 | 2012 | 16 | 0.130 |
Why?
| Anxiety | 1 | 2013 | 159 | 0.130 |
Why?
| Lipids | 1 | 1993 | 142 | 0.130 |
Why?
| Pleural Effusion | 1 | 2012 | 29 | 0.130 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2012 | 16 | 0.130 |
Why?
| Drug Administration Schedule | 3 | 2019 | 290 | 0.130 |
Why?
| Emergencies | 1 | 2012 | 46 | 0.130 |
Why?
| Catheters | 1 | 2011 | 17 | 0.130 |
Why?
| Erythrocyte Count | 1 | 2011 | 9 | 0.130 |
Why?
| Acute Disease | 3 | 2018 | 428 | 0.130 |
Why?
| Intestinal Perforation | 1 | 2011 | 40 | 0.130 |
Why?
| C-Reactive Protein | 3 | 2017 | 76 | 0.130 |
Why?
| Singapore | 1 | 2011 | 3 | 0.130 |
Why?
| Thailand | 1 | 2011 | 8 | 0.130 |
Why?
| Vietnam | 1 | 2011 | 9 | 0.120 |
Why?
| Anal Canal | 1 | 2011 | 42 | 0.120 |
Why?
| Cerebrospinal Fluid | 1 | 2011 | 42 | 0.120 |
Why?
| Chronic Pain | 1 | 2012 | 70 | 0.120 |
Why?
| Alkalosis | 1 | 2010 | 1 | 0.120 |
Why?
| Confusion | 1 | 2010 | 7 | 0.120 |
Why?
| Respiratory Rate | 1 | 2010 | 11 | 0.120 |
Why?
| Spinal Puncture | 1 | 2011 | 50 | 0.120 |
Why?
| Cognition | 1 | 1994 | 343 | 0.120 |
Why?
| Reminder Systems | 1 | 2010 | 9 | 0.120 |
Why?
| Pylorus | 1 | 2010 | 18 | 0.120 |
Why?
| Developmental Disabilities | 1 | 1994 | 343 | 0.120 |
Why?
| Aspirin | 1 | 2010 | 63 | 0.120 |
Why?
| Chronic Disease | 1 | 2013 | 484 | 0.120 |
Why?
| Focal Epithelial Hyperplasia | 1 | 2010 | 2 | 0.120 |
Why?
| Alphapapillomavirus | 1 | 2010 | 4 | 0.120 |
Why?
| Papillomavirus Infections | 1 | 2010 | 20 | 0.120 |
Why?
| Gastrostomy | 1 | 2011 | 94 | 0.120 |
Why?
| Hospitals, Public | 1 | 2010 | 3 | 0.120 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 122 | 0.110 |
Why?
| Anemia, Sickle Cell | 1 | 2012 | 172 | 0.110 |
Why?
| Early Diagnosis | 1 | 2010 | 89 | 0.110 |
Why?
| Fever of Unknown Origin | 1 | 2009 | 10 | 0.110 |
Why?
| Escherichia coli Infections | 1 | 2010 | 76 | 0.110 |
Why?
| Diagnostic Tests, Routine | 1 | 2009 | 37 | 0.110 |
Why?
| Body Temperature | 1 | 2009 | 31 | 0.110 |
Why?
| Kidney | 1 | 1993 | 476 | 0.110 |
Why?
| Sensitivity and Specificity | 2 | 2020 | 955 | 0.110 |
Why?
| Herpesvirus 3, Human | 1 | 2008 | 11 | 0.110 |
Why?
| Herpes Zoster | 1 | 2008 | 8 | 0.110 |
Why?
| Hospitalization | 3 | 2020 | 414 | 0.110 |
Why?
| Chickenpox Vaccine | 1 | 2008 | 10 | 0.110 |
Why?
| Brain | 1 | 2019 | 1569 | 0.100 |
Why?
| Clinical Competence | 2 | 2009 | 292 | 0.100 |
Why?
| Insurance, Pharmaceutical Services | 1 | 2008 | 11 | 0.100 |
Why?
| Antimalarials | 1 | 2008 | 22 | 0.100 |
Why?
| Drug Resistance | 1 | 2008 | 80 | 0.100 |
Why?
| Sex Factors | 1 | 2010 | 476 | 0.100 |
Why?
| Evidence-Based Medicine | 1 | 2010 | 304 | 0.100 |
Why?
| Diagnostic Imaging | 1 | 2009 | 147 | 0.100 |
Why?
| Nose | 1 | 1988 | 58 | 0.100 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 2566 | 0.100 |
Why?
| Foreign Bodies | 1 | 1988 | 32 | 0.100 |
Why?
| Quinolones | 1 | 2008 | 56 | 0.100 |
Why?
| Logistic Models | 2 | 2008 | 520 | 0.100 |
Why?
| Risk Factors | 5 | 2020 | 2687 | 0.090 |
Why?
| Drug Resistance, Bacterial | 2 | 2016 | 47 | 0.090 |
Why?
| Microbial Sensitivity Tests | 2 | 2016 | 96 | 0.090 |
Why?
| Particle Size | 1 | 2006 | 41 | 0.090 |
Why?
| Administration, Intravenous | 2 | 2018 | 44 | 0.090 |
Why?
| Forms and Records Control | 1 | 2005 | 10 | 0.090 |
Why?
| Risk Management | 1 | 2005 | 8 | 0.090 |
Why?
| Felodipine | 2 | 1996 | 2 | 0.090 |
Why?
| Water | 1 | 2006 | 53 | 0.090 |
Why?
| Bacteremia | 2 | 2017 | 65 | 0.090 |
Why?
| Single-Blind Method | 1 | 2006 | 111 | 0.090 |
Why?
| Risk Assessment | 1 | 2010 | 910 | 0.090 |
Why?
| Ointments | 1 | 2005 | 26 | 0.080 |
Why?
| Administration, Inhalation | 1 | 2006 | 192 | 0.080 |
Why?
| Liposomes | 1 | 2005 | 86 | 0.080 |
Why?
| Agglutination Tests | 1 | 2004 | 3 | 0.080 |
Why?
| Rural Health | 1 | 2004 | 19 | 0.080 |
Why?
| Malaria | 1 | 2004 | 26 | 0.080 |
Why?
| Catheterization, Peripheral | 1 | 2005 | 70 | 0.080 |
Why?
| Prognosis | 1 | 2010 | 1606 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 157 | 0.080 |
Why?
| Sampling Studies | 1 | 2003 | 35 | 0.080 |
Why?
| Body Image | 1 | 2003 | 31 | 0.080 |
Why?
| Dietary Proteins | 1 | 2004 | 108 | 0.070 |
Why?
| Double-Blind Method | 1 | 2005 | 477 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 2 | 2017 | 587 | 0.070 |
Why?
| Decision Support Techniques | 1 | 2004 | 114 | 0.070 |
Why?
| Suppositories | 1 | 2002 | 2 | 0.070 |
Why?
| Case-Control Studies | 2 | 2019 | 1196 | 0.070 |
Why?
| Drug Monitoring | 1 | 2003 | 83 | 0.070 |
Why?
| Epilepsy | 2 | 2019 | 603 | 0.070 |
Why?
| Patient Education as Topic | 1 | 2003 | 163 | 0.070 |
Why?
| Health Education | 1 | 2002 | 59 | 0.070 |
Why?
| Statistics, Nonparametric | 2 | 2017 | 238 | 0.060 |
Why?
| Near Drowning | 1 | 2020 | 1 | 0.060 |
Why?
| Oceans and Seas | 1 | 2020 | 2 | 0.060 |
Why?
| Swimming Pools | 1 | 2020 | 5 | 0.060 |
Why?
| Pharyngitis | 1 | 2020 | 15 | 0.060 |
Why?
| Suicide, Attempted | 2 | 2010 | 21 | 0.060 |
Why?
| Reoperation | 2 | 2012 | 439 | 0.060 |
Why?
| Aged | 2 | 2018 | 1465 | 0.060 |
Why?
| Abdomen | 1 | 2020 | 59 | 0.060 |
Why?
| Intestinal Obstruction | 1 | 2020 | 63 | 0.060 |
Why?
| Tomography, X-Ray Computed | 2 | 2016 | 985 | 0.060 |
Why?
| Cardiopulmonary Resuscitation | 1 | 2020 | 80 | 0.050 |
Why?
| Ammonia | 1 | 2019 | 25 | 0.050 |
Why?
| Mutation | 1 | 2008 | 2013 | 0.050 |
Why?
| DNA, Viral | 2 | 2010 | 66 | 0.050 |
Why?
| Cause of Death | 1 | 2020 | 158 | 0.050 |
Why?
| Plasma | 1 | 2019 | 24 | 0.050 |
Why?
| Intestine, Small | 1 | 2020 | 115 | 0.050 |
Why?
| Mediterranean Sea | 1 | 2018 | 1 | 0.050 |
Why?
| Scyphozoa | 1 | 2018 | 1 | 0.050 |
Why?
| Blood Coagulation Tests | 1 | 2019 | 33 | 0.050 |
Why?
| Immunoglobulins | 1 | 2019 | 42 | 0.050 |
Why?
| Prednisolone | 1 | 2019 | 27 | 0.050 |
Why?
| Blood Coagulation | 1 | 2019 | 56 | 0.050 |
Why?
| Analysis of Variance | 1 | 2020 | 457 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2019 | 180 | 0.050 |
Why?
| Myoglobinuria | 1 | 2018 | 2 | 0.050 |
Why?
| Creatine Kinase | 1 | 2018 | 16 | 0.050 |
Why?
| Seasons | 1 | 2018 | 83 | 0.050 |
Why?
| Poison Control Centers | 1 | 2018 | 4 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2010 | 411 | 0.050 |
Why?
| Internship and Residency | 2 | 2013 | 161 | 0.050 |
Why?
| Colorado | 1 | 2017 | 12 | 0.050 |
Why?
| Parents | 1 | 2004 | 693 | 0.050 |
Why?
| Viperidae | 1 | 2017 | 1 | 0.050 |
Why?
| Breath Tests | 1 | 2018 | 116 | 0.050 |
Why?
| Middle Aged | 2 | 2018 | 2785 | 0.050 |
Why?
| Hypotension | 1 | 2017 | 31 | 0.050 |
Why?
| Dopamine D2 Receptor Antagonists | 1 | 2016 | 2 | 0.050 |
Why?
| Edema | 1 | 2017 | 34 | 0.050 |
Why?
| Paratyphoid Fever | 1 | 2016 | 16 | 0.050 |
Why?
| Intensive Care Units, Pediatric | 1 | 2019 | 238 | 0.050 |
Why?
| India | 1 | 2016 | 86 | 0.040 |
Why?
| Calcium Channel Blockers | 1 | 1996 | 37 | 0.040 |
Why?
| Infant Mortality | 1 | 2017 | 171 | 0.040 |
Why?
| Nifedipine | 1 | 1995 | 4 | 0.040 |
Why?
| Hypertension, Renal | 1 | 1995 | 13 | 0.040 |
Why?
| Pneumonia, Bacterial | 1 | 2015 | 31 | 0.040 |
Why?
| Isotonic Solutions | 1 | 2015 | 12 | 0.040 |
Why?
| Antihypertensive Agents | 1 | 1995 | 56 | 0.040 |
Why?
| Adjuvants, Anesthesia | 1 | 2014 | 1 | 0.040 |
Why?
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2014 | 7 | 0.040 |
Why?
| Hypnotics and Sedatives | 1 | 2014 | 36 | 0.040 |
Why?
| Urinary Tract Infections | 1 | 2015 | 65 | 0.040 |
Why?
| Treatment Failure | 1 | 2015 | 175 | 0.040 |
Why?
| Ileum | 1 | 2014 | 81 | 0.040 |
Why?
| Psychological Tests | 1 | 2013 | 52 | 0.040 |
Why?
| Intelligence Tests | 1 | 1994 | 136 | 0.040 |
Why?
| Medical History Taking | 1 | 2013 | 24 | 0.040 |
Why?
| Longitudinal Studies | 1 | 2016 | 770 | 0.040 |
Why?
| Basal Ganglia | 1 | 2013 | 40 | 0.040 |
Why?
| Biopsy | 1 | 2014 | 331 | 0.040 |
Why?
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 1993 | 7 | 0.040 |
Why?
| Aldosterone | 1 | 1993 | 14 | 0.040 |
Why?
| Radiology | 1 | 2013 | 32 | 0.040 |
Why?
| Kidney Tubules, Collecting | 1 | 1993 | 15 | 0.040 |
Why?
| Kidney Tubules | 1 | 1993 | 30 | 0.040 |
Why?
| Lipoproteins, HDL | 1 | 1993 | 27 | 0.040 |
Why?
| Inflammatory Bowel Diseases | 1 | 2014 | 135 | 0.030 |
Why?
| Alprostadil | 1 | 1992 | 13 | 0.030 |
Why?
| Drug Therapy | 1 | 1993 | 39 | 0.030 |
Why?
| Blood Proteins | 1 | 1993 | 55 | 0.030 |
Why?
| Hyperlipidemias | 1 | 1993 | 44 | 0.030 |
Why?
| Pregnancy Outcome | 1 | 1994 | 244 | 0.030 |
Why?
| Clarithromycin | 1 | 2012 | 12 | 0.030 |
Why?
| Length of Stay | 1 | 2014 | 345 | 0.030 |
Why?
| Lung Diseases, Interstitial | 1 | 2012 | 24 | 0.030 |
Why?
| Amikacin | 1 | 2012 | 7 | 0.030 |
Why?
| Triglycerides | 1 | 1993 | 114 | 0.030 |
Why?
| Abdominal Cavity | 1 | 2012 | 5 | 0.030 |
Why?
| Chest Tubes | 1 | 2012 | 22 | 0.030 |
Why?
| Cholesterol | 1 | 1993 | 140 | 0.030 |
Why?
| Patient Compliance | 2 | 2008 | 181 | 0.030 |
Why?
| Pregnancy | 2 | 1997 | 1981 | 0.030 |
Why?
| Meningomyelocele | 1 | 2011 | 19 | 0.030 |
Why?
| Child, Hospitalized | 1 | 2012 | 99 | 0.030 |
Why?
| Electronic Health Records | 1 | 2012 | 64 | 0.030 |
Why?
| Referral and Consultation | 1 | 2012 | 155 | 0.030 |
Why?
| Urine | 1 | 2010 | 7 | 0.030 |
Why?
| Drainage | 1 | 2012 | 118 | 0.030 |
Why?
| Sodium Bicarbonate | 1 | 2010 | 3 | 0.030 |
Why?
| Charcoal | 1 | 2010 | 6 | 0.030 |
Why?
| Pregnancy Complications | 1 | 1994 | 269 | 0.030 |
Why?
| Kidney Failure, Chronic | 1 | 1993 | 187 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2010 | 310 | 0.030 |
Why?
| Respiratory Function Tests | 2 | 2008 | 262 | 0.030 |
Why?
| Hospitals, University | 1 | 2009 | 30 | 0.030 |
Why?
| Electroencephalography | 1 | 2013 | 717 | 0.030 |
Why?
| Glucose | 1 | 2010 | 154 | 0.030 |
Why?
| Hydrocephalus | 1 | 2011 | 213 | 0.030 |
Why?
| Plasmodium vivax | 1 | 2008 | 1 | 0.030 |
Why?
| Malaria, Vivax | 1 | 2008 | 1 | 0.030 |
Why?
| South America | 1 | 2008 | 12 | 0.030 |
Why?
| Status Asthmaticus | 1 | 2008 | 8 | 0.030 |
Why?
| Birth Weight | 1 | 2009 | 159 | 0.030 |
Why?
| Confidence Intervals | 1 | 2008 | 102 | 0.030 |
Why?
| Urban Population | 1 | 2008 | 104 | 0.020 |
Why?
| Odds Ratio | 1 | 2008 | 220 | 0.020 |
Why?
| Gestational Age | 1 | 2009 | 547 | 0.020 |
Why?
| Ketotifen | 1 | 1987 | 6 | 0.020 |
Why?
| Theophylline | 1 | 1987 | 16 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2008 | 275 | 0.020 |
Why?
| Recurrence | 1 | 2008 | 566 | 0.020 |
Why?
| Medication Systems, Hospital | 1 | 2006 | 2 | 0.020 |
Why?
| Delayed-Action Preparations | 2 | 1996 | 22 | 0.020 |
Why?
| Databases as Topic | 1 | 2005 | 31 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2003 | 210 | 0.020 |
Why?
| Half-Life | 2 | 1996 | 43 | 0.020 |
Why?
| Pharmaceutical Preparations | 1 | 2002 | 37 | 0.020 |
Why?
| Fingers | 1 | 1997 | 30 | 0.010 |
Why?
| Microcephaly | 1 | 1997 | 50 | 0.010 |
Why?
| Craniofacial Abnormalities | 1 | 1997 | 73 | 0.010 |
Why?
| Cross-Over Studies | 1 | 1995 | 138 | 0.010 |
Why?
| Pyloric Antrum | 1 | 1992 | 13 | 0.010 |
Why?
| Infusions, Parenteral | 1 | 1992 | 24 | 0.010 |
Why?
| Hyperplasia | 1 | 1992 | 61 | 0.010 |
Why?
| Ductus Arteriosus | 1 | 1992 | 30 | 0.010 |
Why?
| Gastric Mucosa | 1 | 1992 | 46 | 0.010 |
Why?
| Hypertension, Pulmonary | 1 | 1992 | 216 | 0.010 |
Why?
| Echocardiography | 1 | 1992 | 579 | 0.010 |
Why?
| Drug Interactions | 1 | 1987 | 64 | 0.010 |
Why?
| Hemodynamics | 1 | 1987 | 399 | 0.000 |
Why?
| Heart Defects, Congenital | 1 | 1992 | 1067 | 0.000 |
Why?
|
|
Scolnik's networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|